切换导航
  • 比较产品
我的购物车

EasySep™人祖细胞富集试剂盒II

免疫磁珠负选试剂盒
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17936_C

免疫磁珠负选试剂盒

产品优势

  • 操作简单、快捷，且无需分离柱
  • 纯度高达95%
  • 获得的活细胞无标记

产品组分包括

  • EasySep™人祖细胞富集试剂盒II（产品号 #17936）
    • EasySep™人祖细胞富集抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™ 50101 磁珠，2 x 1 mL
  • RoboSep™人祖细胞富集试剂盒II（产品号 #17936RF）
    • EasySep™人祖细胞富集抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™ 50102磁珠，2 x 1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™过滤吸头（产品号 #20125）
main product photo
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

EasySep™ 人祖细胞富集试剂盒 II 旨在通过负选从新鲜脐血及其他细胞样本中分离造血祖细胞。操作流程包括通过抗体复合物和磁珠标记非目的细胞。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，接着简单地将目的细胞倾倒或吸至一个新的试管中。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
造血干/祖细胞
 
种属
人
 
样本来源
Cord Blood
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
干细胞生物学
 

查看更多 显示更少

Data Figures

The content of CD34+ cells before and after the cell isolation procedure are 0.7% and 82.4%, respectively.

Figure 1. EasySep™ Human Progenitor Cell Enrichment Kit II

Starting with 36- to 48-hour-old cord blood, the CD34+ cell content of the isolated fraction is typically 77.5 ± 16.0% (mean ± SD using the silver EasySep™ Magnet). In the above example, using fresh cord blood, the purities of the start and final isolated fractions are 0.7% and 82.4%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
RoboSep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936RF
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Human Progenitor Cell Enrichment Kit II
Catalog #
17936
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (7)

Hematopoietic Stem and Progenitor Cells - Products for Your Research
Brochure
Hematopoietic Stem and Progenitor Cells - Products for Your Research
Human CD34+ Cell Isolation Product Selection
Brochure
Human CD34+ Cell Isolation Product Selection
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation

Publications (3)

Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15. N. Tsuji et al. Leukemia 2022 jun

Abstract

To determine whether antigen presentation by HLA-DR on hematopoietic stem progenitor cells (HSPCs) is involved in the development of acquired aplastic anemia (AA), we studied the HLA-DR expression on CD45dimCD34+CD38+ cells in the peripheral blood of 61 AA patients including 23 patients possessing HLA-class I allele-lacking (HLA-class I[-]) leukocytes. HLA-DR-lacking (DR[-]) cells accounted for 13.0-57.1% of the total HSPCs in seven (11.5%) patients with HLA-DR15 who did not possess HLA-class I(-) leukocytes. The incubation of sorted DR(-) HSPCs in the presence of IFN-$\gamma$ for 72??h resulted in the full restoration of the DR expression. A comparison of the transcriptome profile between DR(-) and DR(+) HSPCs revealed the lower expression of immune response-related genes including co-stimulatory molecules (e.g., CD48, CD74, and CD86) in DR(-) cells, which was not evident in HLA-class I(-) HSPCs. DR(-) cells were exclusively detected in GPI(+) HSPCs in four patients whose HSPCs could be analyzed separately for GPI(+) and GPI(-) HSPCs. These findings suggest that CD4+ T cells specific to antigens presented by HLA-DR15 on HSPCs may contribute to the development of AA as well as the immune escape of GPI(-) HSPCs in a distinct way from CD8+ T cells recognizing HLA-class I-restricted antigens.
View publication
MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus. E. Bulaeva et al. Blood 2020 jun

Abstract

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to IL3, GM-CSF and SCF on the experimental genesis of a human AML in xenografted immunodeficient mice. Initial experiments showed that normal human CD34+ blood cells transduced with a lentiviral MYC vector and then transplanted into immunodeficient mice produced a hierarchically organized, rapidly fatal and serially transplantable blast population, phenotypically and transcriptionally similar to human AML cells, but only in mice producing IL3, GM-CSF and SCF transgenically, or in regular mice in which the cells were exposed to IL3 or GM-CSF delivered using a co-transduction strategy. In their absence, the MYC+ human cells produced a normal repertoire of lymphoid and myeloid progeny in transplanted mice for many months but, upon transfer to secondary mice producing the human cytokines, the MYC+ cells rapidly generated AML. Indistinguishable diseases were also obtained efficiently from both primitive (CD34+CD38-) and late (GMPs) cells. These findings underscore the critical role that these cytokines can play in activating a malignant state in normally differentiating human hematopoietic cells in which MYC expression has been deregulated. They also introduce a robust experimental model of human leukemogenesis to further elucidate key mechanisms involved and test strategies to suppress them.
View publication
The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML. H. Lin et al. Blood 2020 apr

Abstract

Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. To investigate the role of miRNAs in regulating drug resistance and leukemic stem cell (LSCs) fate, we performed global transcriptome profiling in treatment-na{\{i}}ve chronic myeloid leukemia (CML) stem/progenitor cells and identified that miR-185 levels anticipate their response to ABL tyrosine kinase inhibitors (TKIs). miR-185 functions as a tumor suppressor; its restored expression impaired survival of drug-resistant cells sensitized them to TKIs in vitro and markedly eliminated long-term repopulating LSCs and infiltrating blast cells conferring a survival advantage in pre-clinical xenotransplantation models. Integrative analysis with mRNA profiles uncovered PAK6 as a crucial target of miR-185 and pharmacological inhibition of PAK6 perturbed the RAS/MAPK pathway and mitochondrial activity sensitizing therapy-resistant cells to TKIs. Thus miR-185 presents as a potential predictive biomarker and dual targeting of miR-185-mediated PAK6 activity and BCR-ABL may provide a valuable strategy for overcoming drug resistance in patients."
View publication
View All Publications

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • RoboSep™-S (Catalog #21000)
Sample Source Cord Blood
Selection Method Negative
标记抗体
  1. 抗人CD45抗体，克隆2D1
    抗人CD45抗体，克隆2D1

    抗人CD45的小鼠单克隆IgG1抗体

  2. 抗人CD34抗体，克隆8G12
    抗人CD34抗体，克隆8G12

    小鼠单克隆IgG1抗体，抗人CD34

  3. 抗人CD45抗体，克隆HI30
    抗人CD45抗体，克隆HI30

    小鼠单克隆IgG1抗体，抗人、黑猩猩CD45

  4. 抗人CD34抗体，克隆581
    抗人CD34抗体，克隆581

    小鼠单克隆IgG1抗体，抗人CD34

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。